Hedge Fund - OrbiMed Advisors

Affimed NV (NASDAQ:AFMD) is the subject of a 13D filing from Samuel Isaly's OrbiMed Advisors, which shows that the investment firm has sold off some of its stake in the company over the past couple of...

According to the Schulte, Roth & Zabel’s Activist Investing 2015 Annual Review, 344 companies were targeted by activist investors in 2014, as compared with 291 recorded a year earlier.

You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman.

It is easy to imagine that hedge funds would not reveal their equity positions if it were not for reporting requirements enforced by the Securities and Exchange Commission.

It is commonly known that most hedge fund investors reveal their positions through 13F quarterly filings, but 13D filings tend to provide more insights about their stances on different companies.

Everybody is talking about Bill Ackman's nearly $2 billion losses in Valeant (VRX). Valeant isn't the only stock that is costing hedge funds billions.

As U.S equities have plummeted on global-growth worries, confident hedge funds and other investors have started piling up more shares of companies that are trading on the cheap.

Samuel Isaly’s OrbiMed Advisors is a healthcare fund with $15 billion worth of assets under management.

Dennis Purcell’s Aisling Capital and Samuel Isaly’s OrbiMed Advisors have initiated new positions in Cynapsus Therapeutics Inc (NASDAQ:CYNA). In new filings with the U.S.